Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
Crossref DOI link: https://doi.org/10.1007/s00280-014-2577-7
Published Online: 2014-09-17
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hoch, Ute
Staschen, Carl-Michael
Johnson, Randall K.
Eldon, Michael A.
License valid from 2014-09-17